icad inc. (ICAD): Price and Financial Metrics

icad inc. (ICAD)

Today's Latest Price: $8.74 USD

0.42 (-4.59%)

Updated Sep 28 4:00pm

Add ICAD to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 140 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

ICAD Stock Summary

  • ICAD's price/sales ratio is 7.15; that's higher than the P/S ratio of 82.54% of US stocks.
  • With a year-over-year growth in debt of -46.94%, Icad Inc's debt growth rate surpasses only 5.96% of about US stocks.
  • Over the past twelve months, ICAD has reported earnings growth of 76.53%, putting it ahead of 86.41% of US stocks in our set.
  • Stocks that are quantitatively similar to ICAD, based on their financial statements, market capitalization, and price volatility, are MBII, UPWK, AEHR, STXS, and AVGR.
  • Visit ICAD's SEC page to see the company's official filings. To visit the company's web site, go to www.icadmed.com.
ICAD Daily Price Range
ICAD 52-Week Price Range

ICAD Stock Price Chart Technical Analysis Charts

ICAD Price/Volume Stats

Current price $8.74 52-week high $15.31
Prev. close $9.16 52-week low $5.91
Day low $8.69 Volume 207,798
Day high $9.47 Avg. volume 297,316
50-day MA $9.98 Dividend yield N/A
200-day MA $9.99 Market Cap 200.15M

icad inc. (ICAD) Company Bio

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company was founded in 1984 and is based in Nashua, New Hampshire.

ICAD Latest News Stream

Event/Time News Detail
Loading, please wait...

ICAD Latest Social Stream

Loading social stream, please wait...

View Full ICAD Social Stream

Latest ICAD News From Around the Web

Below are the latest news stories about Icad Inc that investors may wish to consider to help them evaluate ICAD as an investment opportunity.

iCAD Responds to CMS’ Finalized Radiation Oncology Alternative Payment Model

IORT reimbursement unchanged; payment values for alternative, longer courses of radiation therapy reducedNASHUA, N.H., Sept. 20, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, is providing additional comments following the Centers for Medicare & Medicaid Services’ (CMS) publication of a new Innovation Center model designed, according to CMS, to improve the quality of care for cancer patients receiving radiotherapy and reduce Medicare expenditures through bundled payments. CMS indicated that the new Radiation Oncology (RO) Model allows this focus on value-based care by creating simpler, more predictable payments that incentivize cost-efficient and clinically effective treatments to improv...

Yahoo | September 21, 2020

iCAD Announces Compelling Data Supporting Launch of First and Only Commercially Available Technology to Provide Short-Term Breast Cancer Risk Assessment

ProFound AI Risk allows for detection of cancers between screenings based on data from prestigious academic medical center, Karolinska Institutet Research published in Radiology shows technology significantly outperforms existing breast cancer risk models, accelerating movement towards risk-adaptive screeningNASHUA, N.H., Sept. 15, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced compelling data supporting ProFound AI™ Risk was published in the peer-reviewed journal, Radiology.i ProFound AI Risk is the first and only commercially available clinical decision support tool that provides an accurate two-year breast cancer risk estimation that is personalized for each woman, ba...

Yahoo | September 15, 2020

iCAD Hosts Free Virtual Roundtable Event Focusing on Making Informed Decisions for Adopting New AI Solutions and Practical Applications in Healthcare

Leading experts in multiple disciplines to share best practices on leveraging AI in clinical settingsNASHUA, N.H., Sept. 09, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will host a free virtual roundtable event for clinicians, titled “What is Real AI: Adopting Artificial Intelligence,” on September 15, 2020 at 7 pm ET/4 pm PT. Event registration is available via this link: https://register.gotowebinar.com/register/1600095491848475917. “This unique event provides a rare opportunity to learn from leading experts in multiple disciplines hailing from influential companies focused on the criteria for making AI decisions in clinical settings to enhance patient care,” acc...

Yahoo | September 9, 2020

LD Micro 360 Companies --Set to Present this Week.

LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.

Yahoo | September 2, 2020

iCAD to Present at the LD Micro 500 Virtual Conference

NASHUA, N.H., Aug. 27, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that management will present at the LD 500 Virtual Conference, hosted by LD Micro and taking place virtually September 1 – 4, 2020. Michael Klein, Chief Executive of iCAD, is scheduled to host a virtual presentation during the conference as follows and will participate in one-on-one meetings throughout the day.LD 500 Virtual Investor Conference Date:Tuesday, September 1, 2020 Time:11:00am Eastern Time – Track 4 Webcast:https://www.webcaster4.com/Webcast/Page/2019/36075 A live audio webcast and archive of the conference presentation will be available using the webcast link above. For more informat...

Yahoo | August 27, 2020

Read More 'ICAD' Stories Here

ICAD Price Returns

1-mo -13.55%
3-mo -14.23%
6-mo 19.89%
1-year 27.59%
3-year 97.74%
5-year 159.35%
YTD 12.48%
2019 110.00%
2018 7.56%
2017 6.50%
2016 -37.52%
2015 -43.62%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7345 seconds.